← Back to headlines
Insilico Partners with SK Biopharmaceuticals in $2.5B AI Drug Pact
Insilico Medicine has partnered with SK Biopharmaceuticals in a significant $2.5 billion agreement focused on AI-driven drug discovery.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
